Nanoscope Therapeutics Inc., a Dallas-based clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, has appointed Massoud Motamed, Ph.D., as vice president of quality.
Motamed brings nearly a decade of CGMP quality and compliance experience, including extensive experience in manufacturing and regulatory review of gene therapy products.
“Massoud’s experience leading quality and compliance in CGMP manufacturing for gene therapies will be valuable as we progress in our chemistry, manufacturing, and controls (CMC) capabilities. This appointment supports the continued advancement of our optogenetic therapies to restore vision in millions of people blinded by retinal diseases and highlights our evolution as a company,” Nanoscope CEO Sulagna Bhattacharya said in a statement.
“I am thrilled to join the highly motivated team at Nanoscope in the development of its novel approach to treating retinal degenerative disease,” Motamed said in a statement. “I look forward to helping Nanoscope navigate advanced clinical development and upcoming regulatory submissions as the Company continues to progress in its clinical trials.”
Received FDA’s Outstanding Service award
Most recently, Motamed was a CMC reviewer for the Gene Therapy Branch at the Center for Biologics Evaluation and Research (CBER), the center within the U.S. Food and Drug Administration that regulates biological products for human use under applicable federal laws.
Motamed has received many awards including FDA’s Outstanding Service award from the Office of Regulatory Affairs.
He previously was head of quality for the Viral Vector Core at UT Southwestern Medical Center in Dallas and before that, Motamed held appointments as head of auditing and compliance at Cipla, a global pharmaceutical company, as well as an FDA inspector for pharmaceutical quality and compliance.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.